JPH10203988A - Therapeutic agent for nasal polyp and edematous lesion of nasal mucous membrane - Google Patents

Abstract

PROBLEM TO BE SOLVED: To obtain a therapeutic agent for nasal polyp and edematous lesions of the nasal mucous membrane that contains aspirin as an effective agent and is directly applied to the affected part. SOLUTION: This therapeutic agent for nasal polyp and edematous lesions of the nasal mucous membrane, which contains aspirin or its salt as an effective agent in the form of powder, is directly applied to the affected part by spray, inhalation, coating, etc. The aspirin is preferably applied in the form of its salt, preferably DL-lysine salt of aspirin. The most suitable form of this therapeutic agent is powder that passes a screen of 200 mesh (75μm). The direct application assures action of the agent in high concentration, and shows excellent effects such as contraction or disappearance of nasal polyp when the nasal polyp is in the stage of edematous lesion or in the initial stage of nasal polyp formation by applying the agent to the affected part twice or three times a day in dosage of 10-1,000mg, preferably 50-100mg, on the basis of aspirin or its salt.

Description

DETAILED DESCRIPTION OF THE INVENTION

[0001]

BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a therapeutic agent for nasal mushrooms and edema lesions of the nasal mucosa. The present invention relates to a therapeutic agent for edematous lesions of nasal polyps and nasal mucosa to be eliminated.

[0002]

2. Description of the Related Art Nasal mushrooms are localized edematous swellings that occur in the nose and paranasal sinuses, and exhibit symptoms such as rhinorrhea, headache, and olfactory disturbance.
When swollen, it is a disease with nasal obstruction. Although various hypotheses such as the theory of tumor growth of small papillae, the theory of allergy, the theory of bacteria, and the theory of virus infection have been cited as the cause, they have not been clarified yet.

[0003] Conventionally, in the treatment of nasal mushrooms, surgical removal has been performed. Therefore, it has been desired to establish a therapeutic agent for nasal mushrooms and a therapeutic method using the same. At present, topical administration to the affected part by mucopolysaccharide metabolizing enzymes such as hyaluronidase, chondroitin sulfate, and lysozyme chloride, steroidal anti-inflammatory agents such as heclomethasone and their combination, and systemic administration by indomethacin oral administration are performed. However, although these nasal mushroom treatments are effective in some patients,
It has many drawbacks, such as symptoms may worsen, side effects may be severe, and doses may need to be increased in the long term. In addition, there has been no report that aspirin or a salt thereof is effective for nasal mushrooms, and no attempt has been made to treat this drug by attaching it to the affected area in powder form.

[0004]

SUMMARY OF THE INVENTION Accordingly, an object of the present invention is to provide a remedy for nasal mushrooms and edematous lesions of the nasal mucosa which has a remarkable effect on nasal mushrooms and has no side effects.

[0005]

Means for Solving the Problems The present inventors have conducted intensive studies, and as a result, by applying powder of aspirin or a salt thereof directly to the affected area, the drug acts at a high concentration, and the stage of the change in nasal mushrooms, especially edema, Further, the present inventors have found that swelling in the initial stage of nasal mushroom formation is remarkably reduced or eliminated, and have completed the present invention.

That is, the present invention provides a therapeutic agent for nasal polyps and edematous lesions of the nasal mucosa, which is used by using aspirin or a salt thereof as an active ingredient and adhering the active ingredient in powder form to an affected part. Things.

[0007]

BEST MODE FOR CARRYING OUT THE INVENTION In the therapeutic agent of the present invention, aspirin or a salt thereof used as an active ingredient is preferably in the form of a salt, and specifically, aspirin and D
Salts of L-lysine, aspirin and DL-arginine and the like are mentioned, and aspirin DL-lysine salt is particularly preferred.
This aspirin DL-lysine salt is used as an injection for the purpose of antipyretic, analgesic and the like, and its safety has been established. In the present invention, aspirin or a salt thereof may be in the form of a hydrate or a complex.

The aspirin or a salt thereof used in the present invention may be one synthesized according to a conventional method, a commercially available one may be used as it is, or a desired salt form may be used according to a conventional method. Good.

The therapeutic agent of the present invention is required to have a powdery form. Here, the powder means a substance which passes through a sieve No. 50 (300 μm) specified in the Japanese Pharmacopoeia, and has an adhesive property to an affected part. From the viewpoints of adhesion and ease of adhesion, etc., it is preferable that the material pass through the entirety of No. 100 (150 μm), and more preferably that the material completely passes through the No. 200 (75 μm).

Further, the present invention may contain a commonly used pharmaceutically acceptable carrier as long as the effects of the present invention are not impaired.

Examples of such carriers include lubricating agents such as gum arabic, carmellose sodium, stearic acid, palmitic acid and salts thereof, starches, mica, talc; sugars such as glucose, starch, dextrin, dextran, cellulose, and glycine. , Alanine and other amino acids and salts thereof, excipients and stabilizers such as albumin and gelatin; aspartame, sugars such as glucose, sweeteners such as saccharin; kaolin, carmellose sodium, anhydrous silicic acid, magnesium carbonate, etc. Adsorbents such as inorganic salts and activated carbon; mucosal and skin protecting agents such as glycyrrhetinic acid and ethanolamine salts; surfactants such as polyoxyethylene, polyoxypropylene glycol, soybean, egg yolk lecithin, polysorbate, and the like.

[0012] The method of adhering the therapeutic agent of the present invention to the affected area in powder form includes methods such as spraying, inhaling, and applying.

The frequency and amount of administration of the therapeutic agent of the present invention is not particularly limited, but it is preferable that the therapeutic agent is adhered to the affected area two to three times a day, and the active ingredient is aspirin or its salt in an amount of preferably 10 to 1000 mg per dose. And about 50 to 100 mg are particularly preferable. For patients with aspirin hypersensitivity, the dosage may be reduced according to the symptoms within the effective amount.

Nasal mushrooms to which the therapeutic agent of the present invention is administered include:
The type, symptoms, degree of progress, etc. are not particularly limited,
It is particularly effective for those with edematous changes and those in the early stages of nasal mushroom formation.

[0015]

The therapeutic agent of the present invention has an excellent effect of reducing and eliminating nasal mushrooms by adhering them in powder form to nasal mushrooms, particularly those at the stage of edematous change and early stage of nasal mushroom formation.

[0016]

EXAMPLES The present invention will be described in more detail with reference to the following examples, but the present invention is not limited to these examples.

Example 1 Aspirin DL-lysine salt powder (100 mg) was applied twice a week using a cotton swab to both nasal polyps of a nasal polyps with no effect using various nebulizers, antibiotics, enzyme preparations and anti-inflammatory agents. . One month after the start of the treatment, the size of the nasal mushrooms was so small that it could be visually recognized. Thereafter, the same treatment was performed, and no recurrence of the nasal polyps was observed even 8 weeks after the start of the treatment.

Example 2 For a patient with sinusitis and a recurrent history of nasal mushrooms associated therewith and recurring after surgical removal, aspirin DL-lysine salt powder 100 mg twice daily using a nebulizer. Sprayed. One week after the start of the treatment, the edema changes around the entrance of the phloem sinus and the frontal sinus, the middle auricle and the olfactory cleft disappear. Improved.

Example 3 A patient with edematous changes in and around the middle turbinate accompanying sinusitis was subjected to nebulization therapy with aspirin DL-lysine salt in the same manner as in Example 2, and one week after the start of treatment ,
The edematous changes in the middle turbinate disappeared, and symptoms caused by nasal polyps such as rhinorrhea and nasal congestion were improved.

Claims (2)

[Claims] 1. An aspirin or a salt thereof as an active ingredient,
A therapeutic agent for nasal polyps and edematous lesions of the nasal mucosa, which is used by adhering the active ingredient to the affected part in powder form. 2. The method of claim 1, wherein the active ingredient is aspirin DL-lysine salt.